An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Novartis has been steadily building itself into a radio-oncology powerhouse in the last ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.

Novartis has bolstered its foothold in the oncology space with the approvals of certain newer ... its non-COVID operational ...

Novartis presented updated Phase III NATALEE trial results at ESMO 2024, showing that Kisqali (ribociclib) with endocrine ...